Should I buy or sell Adaptimmune Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ADAP shares. View ADAP analyst ratings or view top-rated stocks .

What is Adaptimmune Therapeutics' stock price target for 2024?

4 analysts have issued 12-month price targets for Adaptimmune Therapeutics' stock. Their ADAP share price targets range from $1.00 to $10.00. On average, they expect the company's share price to reach $4.65 in the next twelve months. This suggests a possible upside of 753.4% from the stock's current price. View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts .

How have ADAP shares performed in 2023?

Adaptimmune Therapeutics' stock was trading at $1.46 at the beginning of 2023. Since then, ADAP shares have decreased by 62.7% and is now trading at $0.5449. View the best growth stocks for 2023 here .

When is Adaptimmune Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our ADAP earnings forecast .

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) posted its earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). The biotechnology company earned $7.32 million during the quarter, compared to the consensus estimate of $5 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 118.47% and a negative net margin of 133.94%.

What ETF holds Adaptimmune Therapeutics' stock ?

Simplify Propel Opportunities ETF holds 150,000 shares of ADAP stock, representing 0.13% of its portfolio.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com . Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE) , CA (CA) , Endologix (ELGX) , Brainstorm Cell Therapeutics (BCLI) , Second Sight Medical Products (EYES) , Shopify (SHOP) , Micron Technology (MU) , BlackRock (BLK) , Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG) .

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (1.72%), Acuitas Investments LLC (0.05%), Harbor Capital Advisors Inc. (0.01%), Marquette Asset Management LLC (0.01%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adrian Rawcliffe , Cintia Piccina, Elliot Norry , Garry E Menzel, Gavin Wood, John Lunger , William C Bertrand Jr and William C Bertrand, Jr. View institutional ownership trends .

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Adaptimmune Therapeutics Stock Price, News & Analysis (NASDAQ:ADAP)

$0.54

-0.02 (-3.54%)

(As of 12/8/2023 ET)

Compare

Today's Range: $0.53
▼
$0.56
50-Day Range: $0.43
▼
$0.78
52-Week Range: $0.42
▼
$2.35

Volume: 263,717 shs
Average Volume: 468,255 shs
Market Capitalization: $541.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.65

Adaptimmune Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 753.4% Upside
$4.65 Price Target
Short Interest: Bearish
0.60% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.35
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.46) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

811th out of 942 stocks

Biological Products, Except Diagnostic Industry

143rd out of 161 stocks

3.3

Analyst's Opinion

Consensus Rating
Adaptimmune Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $4.65, Adaptimmune Therapeutics has a forecasted upside of 753.4% from its current price of $0.54.
Amount of Analyst Coverage
Adaptimmune Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
0.60% of the outstanding shares of Adaptimmune Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Adaptimmune Therapeutics has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Adaptimmune Therapeutics has recently increased by 2.39%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Adaptimmune Therapeutics does not currently pay a dividend.
Dividend Growth
Adaptimmune Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADAP.

3.0

News and Social Media Coverage

News Sentiment
Adaptimmune Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for ADAP on MarketBeat in the last 30 days.
MarketBeat Follows
7 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.08% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 14.55% of the stock of Adaptimmune Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.46) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adaptimmune Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adaptimmune Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adaptimmune Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADAP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADAP Stock News Headlines

December 7, 2023 | finance.yahoo.com

Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year

December 6, 2023 | finance.yahoo.com

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

December 9, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 6, 2023 | americanbankingnews.com

Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.com

December 3, 2023 | benzinga.com

Adaptimmune Therapeutics Stock (NASDAQ:ADAP) Earnings Dates and Earning Calls

December 3, 2023 | benzinga.com

Adaptimmune Therapeutics Stock (NASDAQ:ADAP) Dividends: History, Yield and Dates

December 2, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Adaptimmune on Strong Pipeline Developments and Market Expansion Potential

November 29, 2023 | finanznachrichten.de

Adaptimmune Therapeutics PLC: Adaptimmune Receives Transfer of IND for Lete-cel Program

December 9, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 29, 2023 | finance.yahoo.com

Adaptimmune Receives Transfer of IND for Lete-cel Program

November 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Vincerx Pharma Inc (VINC) and Pharvaris (PHVS)

November 15, 2023 | finanznachrichten.de

T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment

November 14, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Harpoon Therapeutics (HARP), Disc Medicine (IRON) and Rain Therapeutics (RAIN)

November 13, 2023 | finance.yahoo.com

Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

November 13, 2023 | insidermonkey.com

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript

November 9, 2023 | finance.yahoo.com

Forecast: Analysts Think Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Business Prospects Have Improved Drastically

November 8, 2023 | finance.yahoo.com

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

November 7, 2023 | finance.yahoo.com

Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing

November 7, 2023 | morningstar.com

Adaptimmune Therapeutics PLC ADR ADAP

October 31, 2023 | finance.yahoo.com

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

October 31, 2023 | finance.yahoo.com

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

October 27, 2023 | msn.com

Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights

October 26, 2023 | markets.businessinsider.com

Hold Rating on Adaptimmune Therapeutics Amid Phase I SURPASS Trial Results: Insights on Efficacy, Safety Concerns, and Future Expectations

October 26, 2023 | markets.businessinsider.com

Hold Rating on Adaptimmune Therapeutics: Promising Updates but Significant Uncertainties Persist

October 25, 2023 | finance.yahoo.com

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

October 23, 2023 | finance.yahoo.com

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

September 29, 2023 | markets.businessinsider.com

Buy Rating Issued for Adaptimmune Therapeutics: A Comprehensive Analysis of Future Prospects and Challenges

See More Headlines

Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADAP
CUSIP: N/A
CIK: 1621227
Web: www.adaptimmune.com
Phone: 441235430000
Fax: 44-12-3543-0001
Employees: 534
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.65
High Stock Price Target: $10.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +753.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-165,460,000.00
Net Margins: -133.94%
Pretax Margin: -129.74%
Return on Equity: -118.47%
Return on Assets: -35.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.92
Quick Ratio: 2.92

Sales & Book Value

Annual Sales: $71.08 million
Price / Sales: 7.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.50 per share
Price / Book: 1.09

Miscellaneous

Outstanding Shares: 994,213,000
Free Float: 821,518,000
Market Cap: $541.75 million
Optionable: Optionable
Beta: 1.95

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Adrian G. Rawcliffe (Age 51)
CEO, Principal Accounting Officer & Director
Comp: $693.64k
Mr. Gavin Hilary James Wood ACA (Age 53)
BA (Hons), Chief Financial Officer
Comp: $508.22k
Mr. William C. Bertrand Jr. (Age 58)
Esq., J.D., Chief Operating Officer
Comp: $573.8k
Dr. Elliot Norry B.A. (Age 59)
M.D., Chief Medical Officer
Comp: $549.05k
Dr. Helen Katrina Tayton-Martin MBA (Age 56)
Ph.D., Co-Founder & Chief Business & Strategy Officer
Comp: $709.84k
Ms. Joanna Brewer Ph.D. (Age 47)
Chief Scientific Officer
Dr. Juli P. Miller Ph.D.
VP of Corporate Affairs & Investor Relations
Ms. Kerry Sharp
Senior VP & General Council
Dana Lynch
Senior Director of Corporate Communications
Dr. Rafael G. Amado M.D. (Age 59)
President of Research & Development
Comp: $710.14k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ADAP Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptimmune Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ADAP shares.
View ADAP analyst ratings or view top-rated stocks.
What is Adaptimmune Therapeutics' stock price target for 2024?: 4 analysts have issued 12-month price targets for Adaptimmune Therapeutics' stock. Their ADAP share price targets range from $1.00 to $10.00. On average, they expect the company's share price to reach $4.65 in the next twelve months. This suggests a possible upside of 753.4% from the stock's current price.
View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts.
How have ADAP shares performed in 2023?: Adaptimmune Therapeutics' stock was trading at $1.46 at the beginning of 2023. Since then, ADAP shares have decreased by 62.7% and is now trading at $0.5449.
View the best growth stocks for 2023 here.
When is Adaptimmune Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our ADAP earnings forecast.
How were Adaptimmune Therapeutics' earnings last quarter?: Adaptimmune Therapeutics plc (NASDAQ:ADAP) posted its earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). The biotechnology company earned $7.32 million during the quarter, compared to the consensus estimate of $5 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 118.47% and a negative net margin of 133.94%.
What ETF holds Adaptimmune Therapeutics' stock ?: Simplify Propel Opportunities ETF holds 150,000 shares of ADAP stock, representing 0.13% of its portfolio.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?: 6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Adaptimmune Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).
When did Adaptimmune Therapeutics IPO?: (ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
Who are Adaptimmune Therapeutics' major shareholders?: Adaptimmune Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (1.72%), Acuitas Investments LLC (0.05%), Harbor Capital Advisors Inc. (0.01%), Marquette Asset Management LLC (0.01%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Garry E Menzel, Gavin Wood, John Lunger, William C Bertrand Jr and William C Bertrand, Jr.
View institutional ownership trends.
How do I buy shares of Adaptimmune Therapeutics?: Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ADAP) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial